AMR Clinical Appoints Bernard Dyson as Chief Financial Officer
"Bernard brings an exceptional combination of financial leadership, operational expertise, and strategic vision," said
Dyson brings decades of life sciences and clinical research industry experience, supporting growth initiatives and aligning financial strategy with operational execution. "AMR has built a differentiated clinical research platform with strong momentum and a clear vision for the future. Having spent my career in clinical research and strategic finance, I look forward to partnering with the team to support AMR's next phase of growth," said Dyson.
As sponsors and CROs increasingly seek more efficient and comprehensive approaches to clinical development solutions, AMR Clinical remains focused on bringing treatments to patients through high-quality clinical research. The addition of Dyson reinforces AMR's commitment to strengthening its leadership team as the company continues to grow and innovate.
About AMR Clinical
AMR Clinical is an award-winning clinical research site company specializing in clinical trials across a broad range of therapeutic areas. AMR partners with leading healthcare providers and investigators to deliver high-quality, data-driven research while improving access and outcomes for patients.
Media Contact:
Michael Martin
Vice President of Corporate Development
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/amr-clinical-appoints-bernard-dyson-as-chief-financial-officer-302794958.html
SOURCE AMR Clinical
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tenth Ward Distilling Company Celebrates 10 Years with "X Marks 10 Years" Celebration
- STATEMENT FROM THE RIGMORA BIOTECH INVESTORS
- Embolx Secures New CMS HCPCS Level II G-Code for Pressure-Generating Catheter Procedures Performed in the Physician Office (OBL)
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share